PYX-201 achieves 50% ORR in HNSCC; Merck collaboration for KEYTRUDA combo

Pyxis Oncology, Inc.

PYX-201 achieved 50% confirmed ORR by RECIST 1.1 (1 CR, 2 PR) and 100% DCR in 6 heavily pretreated HNSCC patients.
Overall 26% ORR across six solid tumor types (n=31) with dose-dependent responses; ovarian, NSCLC, breast, sarcoma also showed shrinkage.
Entered Clinical Trial Collaboration with Merck to evaluate PYX-201 + KEYTRUDA in HNSCC, HR+/HER2- breast, TNBC, sarcoma; dosing starts Q1 2025.
PYX-201 generally well-tolerated; low incidence of Grade 3/4 TRAEs; favorable PK profile with increased stability.
Multiple Phase 1 expansion studies and combo studies to begin Q1 2025 with data readouts expected throughout 2025 and 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.